TEE
NAGE

Tibra Equities Europe’s Niagen Bioscience NAGE Stock Holding History

Tibra Equities Europe’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-39,000
Closed -$385K – 205
2021
Q2 		$385K Buy
+39,000
New +$340K 0.12% 35
2018
Q2 		– Sell
-76,158
Closed -$320K – 216
2018
Q1 		$320K Buy
+76,158
New +$399K 0.06% 163

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Tibra Equities Europe's NAGE Position: Q3 2021 in Review

Tibra Equities Europe sold out of Niagen Bioscience (NAGE) in Q3 2021, closing a stake of 39,000 shares — an estimated $385K sold.

Tibra Equities Europe first reported a position in NAGE in Q1 2018 and held it in 2 quarters. The position peaked at $385K in Q2 2021. 86 funds tracked by Wall St. Rank hold NAGE as of Q3 2021.

  • Tibra Equities Europe reported no remaining Niagen Bioscience position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 39,000 Niagen Bioscience shares in Q3 2021, an estimated $385K.
  • Tibra Equities Europe first reported a position in Niagen Bioscience in Q1 2018 and held it in 2 quarters.
  • Tibra Equities Europe's Niagen Bioscience position peaked at $385K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.